New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 4, 2018 - The FDA announced the discontinuation of Recordati Rare Diseases’ Mustargen (mechlorethamine) 10 mg injection.
Download PDF
Return to publications
